Floatz logo

Bozitinib

MET Activating Mutation

Shanghai Pulmonary Hospital, Shanghai, ChinaPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the MET Activating Mutation cohort.

Asset / SponsorPhaseRating
Crizotinib
University Health Network, Toronto
Phase 2B

Same molecule, other indications

Bozitinib is also rated in:

MET Exon 14 MutationDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →